3092P Impact of dose reductions on the efficacy of erdafitinib (Erda) in patients (Pts) with advanced or metastatic urothelial carcinoma (mUC): A post-hoc analysis of the phase III THOR study cohort-1 evaluating Erda versus chemotherapy (Chemo) | Publicación